| Overview |
| bs-11032R-Cy3 |
| Gliomedin Polyclonal Antibody, Cy3 Conjugated |
| WB, IF(IHC-P), IF(IHC-F), IF(ICC) |
| Human, Mouse, Rat |
| Dog, Cow, Sheep, Pig, Horse |
| Specifications |
| Cy3 |
| Rabbit |
| KLH conjugated synthetic peptide derived from human Gliomedin/COLM |
| 365-460/551 |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| Cell membrane |
| CANCER RELATED GENE LIVER 2; Cancer related gene-Liver 2; CLOM; collomin; Colm gene name; COLM; Colmedin; CRG L2; FLJ23917; Gldn gene name; UNC 112; GLDN_HUMAN. |
| Gliomedin is a 551 amino acid protein encoded by the human gene GLDN. Gliomedin is thought to play a role in the formation of the nodes of Ranvier along myelinated axons. Accumulation of Na+ channels at the nodes of Ranvier is a prerequisite for saltatory conduction. In peripheral nerves, clustering of these channels along the axolemma is regulated by myelinating Schwann cells through an unknown mechanism. Gliomedin is a glial ligand for Neurofascin and NrCAM, two axonal immunoglobulin cell adhesion molecules that are associated with Na+ channels at the nodes of Ranvier. Gliomedin is expressed by myelinating Schwann cells and accumulates at the edges of each myelin segment during development, where it aligns with the forming nodes. Gliomedin is a single-pass type II membrane protein localized to the nodes of Ranvier and is specifically expressed in spinal cord, brain, placenta and sciatic nerve. It is more abundant in peripheral than central nervous system. |
| Application Dilution |
| WB |
1:300-5000 |
| IF(IHC-P) |
1:50-200 |
| IF(IHC-F) |
1:50-200 |
| IF(ICC) |
1:50-200 |
Powered by Bioz